The global Aptamer Market was valued at USD 2.34 billion in 2023, and is projected to reach USD 10.88 billion by 2030, implying a robust CAGR of ~24.5% for the period 2023–2030 .
Mordor Intelligence offers a somewhat lower trajectory: a CAGR of ~14.5% from USD 2.05 billion in 2025 to USD 4.03 billion in 2030 .
Despite the discrepancy, both agree on rapid expansion—with Grand View’s ~24–25% CAGR often regarded as representative.

2. Market Segmentation by Application

The global aptamer market is typically broken down into three primary application segments:

1. Diagnostics

2. Therapeutics Development

3. Research & Development (R&D)

These segments differ in share size, growth momentum, and strategic drivers.

3. Segment Insights & CAGR Forecasts

a. Research & Development

• The R&D segment held the largest share in 2022 (~31–35%) of total market value, driven by extensive use of aptamers in screening, biomarker discovery, assay development, and basic research workflows .

• Much of this stems from substitution of antibodies: aptamers offer chemical stability, reproducibility, and affinity with low immunogenicity—especially attractive in high-throughput and academic contexts .

• Growth rate: Mordor Intelligence doesn’t cite explicit CAGR for R&D, but Grand View notes that therapeutics grows fastest, implying R&D may be somewhat slower than ~26% CAGR for therapeutics .

b. Diagnostics

• Diagnostics accounted for about 46.6% share of the market in 2024 (per Mordor Intelligence), making it the largest single application category .

• Growth drivers include demand for high‑sensitivity biosensors (e.g., electrochemical aptamer-based, FET sensors), rapid point-of-care platforms, and pandemic‑era funding toward pathogen detection and biomarker tests .

• CAGR: estimates vary. If overall CAGR is ~14–15%, diagnostics closely tracks overall. Under Grand View’s forecast (~24.5% CAGR from 2023–2030), diagnostics likely grows similarly (~25%). Mordor places total CAGR at ~14.5%, so diagnostic growth may be around that figure.

c. Therapeutics Development

• Therapeutics is the fastest-growing segment, though smaller in absolute value compared to diagnostics and R&D .

• Mordor Intelligence gives the therapeutics segment a CAGR of ~15.67% through 2030 .

• Grand View Research estimates the therapeutics segment growing at a robust ~26.1% CAGR from 2023 to 2030—stronger growth than overall due to emerging clinical candidates, regulatory approvals (e.g., IZERVAY), and novel engineering advances .

4. Drivers & Dynamics by Segment

Research & Development

• Aptamers are widely used for high-throughput ligand screening, target validation, cell‑binding assays, and biomarker identification (e.g. AptaBiD) .

• Their stability, low batch variability, and synthetic production benefits make them lucrative tools in academic, CRO, biotech, and pharma research labs .

• Emerging formats like electrochemical aptamer-based sensors (E-AB) extend R&D uses into organ-on-chip platforms and bioreactor monitoring .

Diagnostics

• Aptamer-based sensors deliver ultra-high sensitivity (sub‑picomolar LoDs), with reusable and reagent‑free formats suitable for POC and decentralized testing .

• Pandemic- and pathogen-based funding accelerates development of rapid diagnostic kits (e.g., lateral flow, breath‑test formats using aptamers) .

Therapeutics

• Approval of IZERVAY (geographic atrophy) in 2023 marks a regulatory turning point. A growing number of aptamer-based drug candidates are entering later-stage trials, particularly in oncology, ophthalmology, and antithrombotic therapies .

• Innovations such as RNA aptamers co-formulated in lipid nanoparticles and bispecific aptamer conjugates significantly expand therapeutic potential .

• AI‑enabled discovery platforms (e.g., UltraSELEX) reduce selection time and cost, enhancing speed to clinic.

5. Segment-Specific CAGR Table

6. Growth Trends & Outlook

• Diagnostics likely remain the leading contributor to market value, with continued investment in ultra-sensitive sensors and POC diagnostics, including environmental and cardiac/cancer biomarkers.

• Therapeutics is the growth engine: regulatory approval, AI-assisted discovery, stabilized RNA aptamers, and bispecific format pipelines will continue to propel high CAGR.

• R&D usage stays fundamental as a discovery backbone; testing innovations—like electrochemical, microfluidic, and organ-on-a-chip platforms—support sustained adoption.

• The future may also see rising interest in peptide aptamers, which Grand View forecasts to grow at ~22.8% CAGR (2023–2030) as diagnostic/therapeutic reagent tools .

7. Summary & Strategic Implications

• R&D: largest in current share, supports foundational innovation; steady but moderate growth.

• Diagnostics: nearly half of current market; growth tied to high-sensitivity biosensors and POC expansion.

• Therapeutics: fastest-growing segment; beneficiaries of regulatory momentum and novel engineering.

Overall CAGR estimates vary by source—from ~14.5% (Mordor) to ~24–25% (Grand View). Diagnostics and R&D growth generally mirror overall trend, while therapeutics often surpass it. These segmentation-based forecasts help companies and investors allocate resources strategically across high-growth verticals.

8. Conclusion

The segmentation study underscores how the aptamer market is increasingly diversified, with Diagnostics dominating current revenue share, R&D maintaining essential pipeline activity, and Therapeutics emerging as the fastest-growing segment. CAGR estimates vary—~15–17% for diagnostics and R&D aligned applications under conservative scenarios, or up to 26% for therapeutics in optimistic models. Outlook through 2030 suggests that cumulative market value from key segments will expand substantially, positioning aptamers as a versatile platform across diagnostics, discovery science, and next-generation therapeutics.